Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
354 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01563354 | 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial(LUNA) | completed | Phase 2 | 124 | Novartis PharmaceuticalsINDUSTRY | 9 | Apr 2, 2021 | clinicaltrials |
| NCT01702558 | A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)(TRAXHER2) | terminated | Phase 2 | 182 | Hoffmann-La Roche |
| 12 |
| Jan 22, 2021 |
| clinicaltrials |
| NCT02092922 | A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM) | completed | Phase 2 | 154 | PfizerINDUSTRY | 8 | Oct 19, 2020 | clinicaltrials |
| NCT00706238 | MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma | terminated | Phase 2 | 5 | GlaxoSmithKlineINDUSTRY | 3 | Oct 8, 2020 | clinicaltrials |
| NCT01915303 | Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease | terminated | Phase 2 | 68 | Novartis PharmaceuticalsINDUSTRY | 16 | Sep 18, 2020 | clinicaltrials |
| NCT02244632 | Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer | completed | Phase 1 / Phase 2 | 105 | Isofol Medical ABINDUSTRY | 4 | Sep 9, 2020 | clinicaltrials |
| NCT02514551 | A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer | completed | Phase 2 | 245 | Eli Lilly and CompanyINDUSTRY | 11 | Jun 17, 2020 | clinicaltrials |
| NCT00524277 | Vaccine Therapy in Treating Patients With Breast Cancer | completed | Phase 2 | 456 | San Antonio Military Medical CenterFED | 3 | Mar 30, 2020 | clinicaltrials |
| NCT02735980 | A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer | completed | Phase 2 | 133 | Eli Lilly and CompanyINDUSTRY | 10 | Mar 17, 2020 | clinicaltrials |
| NCT02902965 | Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma | completed | Phase 2 | 74 | Pharmacyclics Switzerland GmbHINDUSTRY | 6 | Mar 16, 2020 | clinicaltrials |
| NCT02512458 | Study of the Effect of Chemotherapy With Cabazitaxel on Prostate Cancer(CABA-BONE) | completed | Phase 2 | 60 | Hellenic Cooperative Oncology GroupOTHER | 1 | Feb 10, 2020 | clinicaltrials |
| NCT02882308 | Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.(OPHELIA) | completed | Phase 2 | 41 | Hellenic Cooperative Oncology GroupOTHER | 1 | Feb 7, 2020 | clinicaltrials |
| NCT01484275 | A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma | completed | Phase 2 | 85 | Janssen Research & Development, LLCINDUSTRY | 11 | Jan 27, 2020 | clinicaltrials |
| NCT00290355 | Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by Surgery | completed | Phase 2 | 182 | GlaxoSmithKlineINDUSTRY | 14 | Jan 2, 2020 | clinicaltrials |
| NCT00263588 | Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer | completed | Phase 2 | 242 | Novartis PharmaceuticalsINDUSTRY | 17 | Dec 12, 2019 | clinicaltrials |
| NCT02548962 | Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 11 | Pharmacyclics LLC.INDUSTRY | 6 | Nov 21, 2019 | clinicaltrials |
| NCT00401843 | A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 307 | Janssen Research & Development, LLCINDUSTRY | 18 | Nov 19, 2019 | clinicaltrials |
| NCT01602224 | A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM) | completed | Phase 2 | 220 | Eli Lilly and CompanyINDUSTRY | 15 | Oct 8, 2019 | clinicaltrials |
| NCT00875667 | A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)(Sprint) | completed | Phase 2 | 254 | CelgeneINDUSTRY | 14 | Sep 16, 2019 | clinicaltrials |
| NCT01890746 | A Safety and Efficacy Study of Eltrombopag in Subjects With AML | completed | Phase 2 | 148 | Novartis PharmaceuticalsINDUSTRY | 10 | Sep 11, 2019 | clinicaltrials |
| NCT01743365 | Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer(A-GAPP) | completed | Phase 2 | 55 | Hellenic Cooperative Oncology GroupOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT01648465 | Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors | terminated | Phase 2 | 25 | Hellenic Cooperative Oncology GroupOTHER | 1 | Sep 3, 2019 | clinicaltrials |
| NCT01327053 | A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma(BOLT) | completed | Phase 2 | 230 | Novartis PharmaceuticalsINDUSTRY | 12 | Aug 28, 2019 | clinicaltrials |
| NCT02046070 | Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma | completed | Phase 2 | 148 | Millennium Pharmaceuticals, Inc.INDUSTRY | 5 | Jul 17, 2019 | clinicaltrials |
| NCT01935154 | Efficacy Study of Vx001 Vaccine in NSCLC Patients | completed | Phase 2 | 221 | Vaxon BiotechINDUSTRY | 8 | Jun 19, 2019 | clinicaltrials |
| NCT01367665 | STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma | completed | Phase 2 | 1,232 | Hoffmann-La RocheINDUSTRY | 37 | Jun 6, 2019 | clinicaltrials |
| NCT02467907 | Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer | completed | Phase 2 | 152 | Hoffmann-La RocheINDUSTRY | 18 | Jun 3, 2019 | clinicaltrials |
| NCT02632786 | The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis(PRONTO) | completed | Phase 2 | 129 | Prothena Biosciences Ltd.INDUSTRY | 10 | Apr 5, 2019 | clinicaltrials |
| NCT03154047 | Study in Subjects With Light Chain (AL) Amyloidosis | terminated | Phase 2 | 80 | Prothena Biosciences Ltd.INDUSTRY | 10 | Mar 26, 2019 | clinicaltrials |
| NCT02624726 | Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment(MINOAS) | unknown | Phase 2 | 31 | Hellenic Oncology Research GroupOTHER | 1 | Feb 22, 2019 | clinicaltrials |
| NCT02771314 | Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC | unknown | Phase 2 | 48 | Hellenic Oncology Research GroupOTHER | 1 | Feb 22, 2019 | clinicaltrials |
| NCT01881230 | Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)(tnAcity) | completed | Phase 2 / Phase 3 | 191 | CelgeneINDUSTRY | 12 | Feb 21, 2019 | clinicaltrials |
| NCT02012920 | A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer | completed | Phase 2 | 200 | Innocrin PharmaceuticalINDUSTRY | 4 | Feb 1, 2019 | clinicaltrials |
| NCT02269943 | Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma | completed | Phase 2 | 36 | CelgeneINDUSTRY | 9 | Dec 12, 2018 | clinicaltrials |
| NCT03746652 | Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma(DARIA) | unknown | Phase 2 | 50 | Hellenic Society of HematologyOTHER | 1 | Nov 23, 2018 | clinicaltrials |
| NCT01855724 | Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer | terminated | Phase 2 | 29 | Hellenic Cooperative Oncology GroupOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT03000452 | A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)(FUSION-MM-005) | completed | Phase 2 | 18 | CelgeneINDUSTRY | 6 | Oct 16, 2018 | clinicaltrials |
| NCT00777101 | Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer | completed | Phase 2 | 233 | Puma Biotechnology, Inc.INDUSTRY | 31 | Aug 9, 2018 | clinicaltrials |
| NCT01208064 | Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy | terminated | Phase 2 / Phase 3 | 102 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 8 | Jul 12, 2018 | clinicaltrials |
| NCT01860638 | A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma | completed | Phase 2 | 296 | Hoffmann-La RocheINDUSTRY | 15 | Apr 30, 2018 | clinicaltrials |
| NCT03475628 | Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma(REBUILD) | unknown | Phase 2 | 57 | Hellenic Society of HematologyOTHER | 1 | Mar 23, 2018 | clinicaltrials |
| NCT02129257 | Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer(AMALTHEA) | completed | Phase 2 | 73 | Hellenic Cooperative Oncology GroupOTHER | 1 | Oct 24, 2017 | clinicaltrials |
| NCT01784978 | Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer(SUNRISES) | terminated | Phase 2 | 41 | Associació per a la Recerca Oncologica, SpainOTHER | 3 | Oct 2, 2017 | clinicaltrials |
| NCT00478270 | A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Metastatic Bone Disease. | withdrawn | Phase 2 | 0 | Hoffmann-La RocheINDUSTRY | 1 | Aug 16, 2017 | clinicaltrials |
| NCT01693549 | Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With Taxanes | completed | Phase 2 | 84 | Hellenic Cooperative Oncology GroupOTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT02016534 | Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors | terminated | Phase 2 | 60 | AmgenINDUSTRY | 18 | Jul 2, 2017 | clinicaltrials |
| NCT01440374 | A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia(ASPIRE) | completed | Phase 2 | 162 | Novartis PharmaceuticalsINDUSTRY | 22 | Jun 5, 2017 | clinicaltrials |
| NCT01013740 | Lapatinib in Combination With Vinorelbine(VITAL) | completed | Phase 2 | 112 | Novartis PharmaceuticalsINDUSTRY | 10 | May 31, 2017 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials